UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes

Nature reviews. Cancer, 2012-12, Vol.12 (12), p.849-859

2012

Volltextzugriff (PDF)

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

The New England journal of medicine, 2011-06, Vol.364 (26), p.2496-2506

2011

Volltextzugriff (PDF)

scRNAseq and High-Throughput Spatial Analysis of Tumor and Normal Microenvironment in Solid Tumors Reveal a Possible Origin of Circulating Tumor Hybrid Cells

Cancers, 2024-04, Vol.16 (7), p.1444

2024

Volltextzugriff (PDF)

Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities

Proceedings of the National Academy of Sciences - PNAS, 2015-08, Vol.112 (34), p.E4726-E4734

2015

Volltextzugriff (PDF)

Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo

Blood, 2013-04, Vol.121 (16), p.3246-3253

2013

Volltextzugriff (PDF)

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

Journal of clinical oncology, 2012-09, Vol.30 (27), p.3376-3382

2012

Volltextzugriff (PDF)

SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes

Proceedings of the National Academy of Sciences - PNAS, 2022-01, Vol.119 (1)

2022

Volltextzugriff (PDF)

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

Cancer, 2016-06, Vol.122 (12), p.1871-1879

2016

Volltextzugriff (PDF)

Identification of RPS14 as a 5q - syndrome gene by RNA interference screen

Nature (London), 2008-01, Vol.451 (7176), p.335-339

2008

Volltextzugriff (PDF)

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Journal of hematology and oncology, 2017-02, Vol.10 (1), p.55-14, Article 55

2017

Volltextzugriff (PDF)

U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3′ End Formation

Molecular cell, 2016-05, Vol.62 (4), p.479-490

2016

Volltextzugriff (PDF)

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Haematologica (Roma), 2015-04, Vol.100 (4), p.479-488

2015

Volltextzugriff (PDF)

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2134-2139

2012

Volltextzugriff (PDF)

Mutation in SF3B1 gene promotes formation of polyploid giant cells in Leukemia cells

Medical oncology (Northwood, London, England), 2022-04, Vol.39 (6), p.65, Article 65

2022

Volltextzugriff (PDF)

MicroRNAs in myeloproliferative neoplasms

British journal of haematology, 2013-05, Vol.161 (4), p.471-483

2013

Volltextzugriff (PDF)

Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts

Blood, 2014-10, Vol.124 (18), p.2834-2846

2014

Volltextzugriff (PDF)

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

Haematologica (Roma), 2013-12, Vol.98 (12), p.1865-1871

2013

Volltextzugriff (PDF)

Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)

Haematologica (Roma), 2016-06, Vol.101 (6), p.781-788

2016

Volltextzugriff (PDF)

Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

Leukemia research, 2017-01, Vol.52, p.50-57

2017

Volltextzugriff (PDF)

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome

PLoS medicine, 2008-02, Vol.5 (2), p.e35

2008

Volltextzugriff (PDF)

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q− syndrome

Blood, 2011-10, Vol.118 (17), p.4666-4673

2011

Volltextzugriff (PDF)

Rewriting the rules for care of MDS and AML patients in the time of COVID-19

Leukemia research reports, 2020-01, Vol.13, p.100201-100201, Article 100201

2020

Volltextzugriff (PDF)

Combination of 5‐azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia

Cancer, 2008-10, Vol.113 (7), p.1596-1604

2008

Volltextzugriff (PDF)

Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network

Cancer research (Chicago, Ill.), 2009-11, Vol.69 (21), p.8249-8255

2009

Volltextzugriff (PDF)

1 – 25 von 398

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(350)
Mit Volltextzugriff
(338)

Publikationsform

Artikel
(397)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(205)
Science & Technology
(191)
Life Sciences & Biomedicine
(180)
Hematology
(107)
Biological And Medical Sciences
(106)
Medical Sciences
(98)
Oncology
(89)
Male
(88)
Aged
(79)
Female
(78)
Hematologic And Hematopoietic Diseases
(75)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(74)
Middle Aged
(71)
Myelodysplastic Syndromes
(60)
Myelodysplastic Syndromes - Pathology
(57)
Adult
(47)
Myelodysplastic Syndromes - Genetics
(44)
Aged, 80 And Over
(43)
Apoptosis
(41)
Myelodysplastic Syndromes - Drug Therapy
(38)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

scRNAseq and High-Throughput Spatial Analysis of Tumor and Normal Microenvironment in Solid Tumors Reveal a Possible Origin of Circulating Tumor Hybrid Cells

Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities

Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

Identification of RPS14 as a 5q - syndrome gene by RNA interference screen

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3′ End Formation

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

Mutation in SF3B1 gene promotes formation of polyploid giant cells in Leukemia cells

MicroRNAs in myeloproliferative neoplasms

Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms

Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)

Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q− syndrome

Rewriting the rules for care of MDS and AML patients in the time of COVID-19

Combination of 5‐azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia

Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network

Suchergebnisse filtern